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Angiotensinogen (ANG) is the sole substrate of the
renin–angiotensin system (RAS). Clinical studies have shown
that RAS activation may lead to hypertension, a major
cardiovascular and renal risk factor. To delineate the
underlying mechanisms of hypertension-induced
nephropathy, we generated transgenic mice that overexpress
rat ANG (rANG) in the kidney to establish whether intrarenal
RAS activation alone can evoke hypertension and kidney
damage and whether RAS blockade can reverse these effects.
Transgenic mice overexpressing renal rANG were generated
by employing the kidney-specific, androgen-regulated
protein promoter linked to rANG cDNA. This promoter
targets rANG cDNA to renal proximal tubules and responds
to androgen stimulation. Transgenic mice displayed
kidney-specific expression of rANG, significantly increased
blood pressure (BP) and albuminuria in comparison to
non-transgenic littermates. Administration of losartan (an
angiotensin II (type 1)-receptor antagonist) or perindopril
(an angiotensin-converting enzyme inhibitor) reversed these
abnormalities in transgenic animals. Renal injury was evident
on examination of the kidneys in transgenic mice, and
attenuated by losartan and perindopril treatment. We
conclude that the overproduction of ANG alone in the kidney
induces an increase in systemic BP, proteinuria, and renal
injury. RAS blockers prevent these abnormalities. These data
support the role of the intrarenal RAS in the development of
hypertension and renal injury.
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Hypertension is a major risk factor for cardiovascular and
renal morbidity and mortality. Although numerous studies
have implicated the renin–angiotensin system (RAS) in the
development of hypertension and nephropathy, the mechan-
isms by which this occurs remain incompletely delineated.
Traditionally, the effects of the RAS were considered to be the
result of circulating components of this system. Physiological,
biochemical, and molecular studies have provided, however,
convincing evidence for other pathways of angiotensin II
(Ang II) production. Among these, the intrarenal RAS is of
special interest. Renal proximal tubules (RPTs) contain all
components of the RAS.1–3 It has been demonstrated that
activation of the Ang II (type 1) receptor (AT1R) in proximal
tubules stimulates the apical sodium–hydrogen exchanger4
and, more distally, augments epithelial sodium channel
activity in the collecting ducts.5,6 Consequently, AT1R
activation in the kidney modulates blood pressure (BP) and
fluid homeostasis. Furthermore, dysregulation of the intra-
renal RAS has been implicated in certain models of
hypertension.7–9
Overexpression of both human angiotensinogen (hANG)
and human renin (hREN) cDNA in RPTs contributes directly
to the development of hypertension independently of
systemic RAS activation in transgenic mice.10–14 It appears,
however, that losartan (an AT1R antagonist) is not parti-
cularly effective in lowering BP in these double transgenic
(hANG and hREN) mice.11,14 Thus, the question remains
whether intrarenal RAS activation alone could induce
hypertension and renal injury independently of systemic
RAS activation, and whether other RAS blockers could block
intrarenal RAS activation.
The objective of our present studies was to investigate
whether a model characterized by activation of the intrarenal
RAS in the absence of activation of the circulating RAS or
other tissue RAS could elicit hypertension and renal injury.
A second objective was to determine whether RAS blockade
could reverse these effects.
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RESULTS
Tissue-specific expression of kidney androgen-regulated
promoter (KAP2)-rat angiotensinogen (rANG) transgene in
transgenic mice
KAP2-rANG transgenic mice were generated to produce
specific and inducible expression of rANG in RPTs. This was
accomplished by inserting rANG cDNA into a construct
containing the KAP promoter and exons 3–5 of hANG gene,
including non-coding DNA at the 30 terminal (Figure 1a).
The non-coding region is necessary to obtain transgene
expression since it contains enhancer elements that are
present downstream of hANG gene.14 Southern blot analysis
revealed the presence of the transgene in heterozygote and
homozygote animals (Figure 1b).
Figure 2 displays the specific reverse transcription-
polymerase chain reaction (RT-PCR) analysis of two (lines
#351 and #388) of five transgenic lines. Testosterone strongly
evoked transgene expression in the kidney. Transgene
expression was not seen in the other tissues (liver, spleen,
lung, heart, brain, testis, and ovaries) of transgenic mice as
well as in tissues of non-transgenic littermates and transgenic
female without testosterone induction.
Figure 3 shows that strong ANG protein expression was
observed in RPTs of neonatal transgenic mice (F4 generation)
in comparison to RPTs of neonatal non-transgenic litter-
mates by employing rabbit anti-rANG polyclonal antibodies.
Western blot analysis reveals that recombinant rANG-HA
fusion protein was detected in RPT extracts of transgenic
mice induced with testosterone by employing anti-HA
antibodies (Figure 4a), but no rANG-HA fusion protein
was detected in the plasma (Figure 4b). Anti-HA antibodies
also interacted well with the recombinant rANG-HA fusion
protein that expressed in COS-7 cells. In contrast, immuno-
reactive ANG was detected in mouse plasma by employing
rabbit anti-rANG polyclonal antibodies with an apparent
molecular weight slightly lower to recombinant rANG-HA
fusion protein that is expressed in COS-7 cells (Figure 4c).
Effect of intrarenal rANG expression in transgenic mice
Figure 5a shows that BP was significantly elevated (Po0.05)
by 20–30 mmHg in transgenic animals at 82 days after
KAP promoter
1542:KAP
promoter Bgl -IIII
rANG cDNA
III
Not I
IV
BamHI
Human angiotensinogen
SpeI NdeI
# 388
# 388 F2 # 351 F2
# 388 F3 # 351 F3
+ M
+ M
+ M
WT Male Female
Male
Male
Male
Male
Female
Female
Female
Female
Male Female
# 351 Founder
a
b
Figure 1 | (a) Schematic map of the kidney androgen-regulated
promoter (KAP2)-rat angiotensinogen (rANG) construct. The
rANG gene was inserted into the NotI sites in exon II. The transgene
was excised as a SpeI and NdeI fragment for microinjection.
(b) Southern blot analysis of tail biopsies for the F2 and F3 generation
of transgenic mice. The extracted genomic DNA was digested with
BamHI and migrated onto 0.8% agarose gel. The positive control (þ )
is composed of 10 pg of rANG cDNA insert mixed with 10 mg of
wild-type BamHI-digested genomic DNA. M, DNA markers (l phage
DNA digested by restriction enzyme, HindIII). WT, wild-type control
littermate.
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Figure 2 | Transgene expression. Southern blot of RT-PCR product
showing tissue expression of rANG mRNA in testosterone-inducible
expression of rANG in (a) male and (b) female induced and
uninduced transgenic mice. The rANG and b-actin fragments are
indicated. Male and female wild-type control (WT ctrl) and transgenic
(lines #388 and #351) mice were induced with testosterone for 2
weeks prior to RNA isolation. K, kidney; L, liver; S, spleen; Lu, lung;
H, heart; B, brain; T, testes, and O, ovary.
Figure 3 | Immunohistochemical staining of ANG in neonatal
mouse kidney by employing rabbit anti-rANG polyclonal
antibodies. (a) Control non-transgenic kidney. (b) Transgenic
neonatal kidney (F4 generation). Original magnification  400.
Kidney International (2006) 69, 1016–1023 1017
S Sachetelli et al.: Intrarenal angiotensinogen expression in transgenic mice o r i g i n a l a r t i c l e
testosterone treatment but not in non-transgenic wild-type
mice. Testosterone elicited a significant increase (Po0.05) in
the kidney to body weight ratio in both transgenic and non-
transgenic animals (Figure 5b). Most interestingly, urinary
proteins were significantly higher in transgenic mice
(Po0.05) but not in non-transgenic controls (Figure 5c).
These data indicate that overexpression of intrarenal rANG
appears to be capable of inducing high blood pressure (HBP)
and proteinuria in transgenic mice.
A longitudinal study was performed to examine the
development of HBP and kidney injury in non-transgenic
and transgenic mice. Figure 6 depicts BP over time in non-
transgenic mice and demonstrates that there was no
significant change of BP in female (a) and male (b) non-
transgenic mice with testosterone induction for a period of
83 days.
Figure 7 depicts BP in transgenic mice and illustrates the
BP difference from baseline in female and male transgenic
mice, respectively, for the #388 line during an 83-day period
with or without RAS blockers. Note that the #351 line is not
included, since results were essentially the same as to those of
the #388 transgenic line. It was apparent that significant HBP
(Po0.05) had developed in all transgenic mice after 7 days of
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Figure 4 | Western blot analysis of recombinant rANG-HA in
mouse RPT extracts and plasma samples. (a) Western blotting with
mouse anti-HA monoclonal antibodies. Lane 1, cellular extract from
COS-7 cells transfected with pcDNA 3.1/rANG-HA, 50 mg; lanes 2 and
3, transgenic mouse RPTs with testosterone induction, 30 mg each;
lanes 4 and 5, transgenic mouse RPTs without testosterone induction,
30mg each: Lanes 6 and 7, non-transgenic mouse RPTs with or
without testosterone induction, 30mg each. (b) Lanes 1 and 6, cellular
extract from COS-7 cells transfected with pcDNA 3.1/rANG-HA, 30mg
and 50 mg, respectively; lanes 2 and 3, transgenic mouse plasma with
and without testosterone induction, 1 ml each; lanes 4 and 5, non-
transgenic mouse plasma with and without testosterone induction,
1 ml each. (c) Western blotting with rabbit anti-rANG polyclonal
antibodies. Lanes 1 and 6, cellular extract from COS-7 cells
transfected with pcDNA 3.1/rANG-HA, 30 mg and 50mg, respectively;
lanes 2 and 3, transgenic mouse plasma with and without
testosterone induction, 1 ml each; lanes 4 and 5, non-transgenic
mouse plasma with and without testosterone induction, 1 ml each.
The apparent molecular weight of ANG-HA is indicated on the left of
each panel, respectively.
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Figure 5 | Cross-sectional study of blood pressure, renal size, and
proteinuria in non-transgenic and transgenic mice after 82 days
of testosterone (T) induction. (a) Mean systolic BP in non-transgenic
wild-type (WT) and transgenic (Tg) mice without (empty bars) or with
testosterone administration for 82 days (black bars). (b) Kidney to
body weight ratio. (c) Protein level in urine samples of wild-type and
transgenic mice. All data are expressed as means7s.e., n¼ 8. *Po0.05.
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Figure 6 | Longitudinal study of systolic BP in non-transgenic
mice. (a, b) The change in mean systolic BP in female and male non-
transgenic mice with or with testosterone induction for an 83-day
period, respectively. Baseline BP was measured in all mice of the
different groups for a week before the experiment. Female mice
treated with placebo (J) or testosterone (K) pellet. Male mice
treated with placebo (&) or testosterone (’) pellet. The placebo
control and testosterone-treated groups were analyzed statistically.
Values are expressed as means7s.e., n¼ 4. NS denotes values that
are not statistically significant.
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induction with testosterone (without treatment with RAS
blockers) and continued until 83 days compared to the
placebo controls. Treatment with losartan or perindopril
(starting at day 14) significantly prevented HBP development
in transgenic mice with testosterone induction. Perindopril
seemed to be more effective than losartan in decreasing BP in
female transgenic mice (Figure 7a) than in male transgenic
mice (Figure 7b). There was no significant difference in
urinary ketone excretion between transgenic and non-
transgenic animals (data not shown).
Figure 8 depicts urinary microalbumin excretion after day
75. This figure shows that both female and male transgenic
mice (testosterone treated) exhibited microalbuminuria as
compared to placebo controls (Po0.05). Treatment with
losartan or perindopril significantly reduced albumin levels
(Po0.05). Again, perindopril seemed to be more effective
than losartan in lowering urinary albumin in female
transgenic mice (Figure 8a) than in male transgenic mice
(Figure 8b).
Histological studies
Hematoxylin–phloxin–saffran (HPS) staining was undertaken
to analyze histologic changes in the non-transgenic and
transgenic kidneys (Figures 9 and 10). Non-transgenic female
littermates had normal kidneys, irrespective of testosterone
administration (Figure 9a and b). However, with exogenous
testosterone, transgenic female kidneys displayed cellular
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Figure 7 | Longitudinal study of systolic BP in the #388 transgenic
line. (a, b) The change in mean systolic BP in female and male
transgenic mice, respectively. Transgenic mice treated with placebo
(J), testosterone (K), testosterone plus losartan (m), and testos-
terone with perindopril (’) for an 83-day period. Baseline BP was
measured in all mice of the different groups for a week before the
experiment. Treatment with RAS inhibitors was started after 14 days
of induction (indicated by the arrow). The placebo control and
testosterone-treated groups with or without losartan or perindopril
treatment were compared statistically. Values are expressed as
means7s.e., n¼ 4. *Po0.05.
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Figure 8 | Microalbuminuria in (a) female and (b) male transgenic
mice after 83 days of induction with testosterone. Urine samples
were collected in metabolic cages at day 82 for a 24-h period. The
urine was then analyzed for albumin and creatinine content. The
results are expressed as means7s.e., n¼ 4. *Po0.05; NS, not
significant.
Figure 9 | Hematoxylin–phloxin–saffran staining of female trans-
genic mice after 83 days of induction with testosterone (Original
magnification  400). (a) Uninduced female control littermate,
(b) testosterone-induced female control littermate, (c) uninduced
female transgenic animal, (d) testosterone-induced female transgenic
animal, (e) testosterone-induced female transgenic animalþ losartan,
and (f) testosterone-induced female transgenic animalþperindopril.
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edema, reabsorption of droplets, and an increase in proximal
tubular cell size with narrowing of the tubular lumen (Figure
9d) as compared to the transgenic placebo controls (Figure
9c). Losartan and perindopril appeared to be renoprotective,
ameliorating these pathological findings (Figure 9e and f). In
contrast, male transgenic mice exhibited no apparent renal
pathology with testosterone administration, and their renal
histology was similar to that of their non-transgenic
littermates (Figure 10).
DISCUSSION
To assess the relative significance of ANG in the proximal
tubules, we generated transgenic mice that overexpress rANG
gene in the kidney after induction with testosterone. The
present studies demonstrate that overexpression of renal
rANG alone induces hypertension and albuminuria in
transgenic mice and that RAS blockade reverses these
abnormalities. The data indicate an important role for the
intrarenal RAS in the development of hypertension and renal
injury independently of systemic RAS activation.
The transgene expression in our model is kidney specific.
ANG protein was readily detectable in RPTs of transgenic
mice but weakly in RPTs of non-transgenic mice. Our results
are consistent with previous investigations in that the KAP2
promoter drives hANG expression in RPTs of transgenic
mice.10–14 Most importantly, we could not detect rANG-HA
fusion protein in the plasma, indicating it is unlikely that
rANG-HA fusion protein expressed in RPTs of transgenic
mice would leak into the circulation to induce hypertension.
We failed to detect HA-staining in RPTs and other organs of
transgenic mice by employing mouse anti-HA monoclonal
antibodies (data not shown). At present, we have no
explanation for this observation. One possible explanation
might be that the affinity of our monoclonal antibodies
(12CA5) might not be sufficiently high to interact with
rANG-HA proteins in transgenic RPTs. In contrast, our
monoclonal antibodies interacted with recombinant rANG-
HA expressed in mouse transgenic RPTs induced by
testosterone and in COS-7 cells by Western blotting. Clearly,
more studies are needed to clarify this discrepancy.
The basal BP in male transgenic mice is not significantly
higher than in non-transgenic males. At the present, the exact
reason(s) for these observations are not clear. One likely
explanation might be that the renin gene expression is
downregulated by intrarenal Ang II (a negative feedback
mechanism) in males as shown previously.14 Clearly, more
studies are needed to explore these intriguing observations.
On the other hand, transgenic mice with exogenous
testosterone administration had significantly higher BP than
either non-transgenic littermates or transgenic mice that
received placebo. In our cross-sectional experiment (82 days),
male and female transgenic mice with testosterone induction
had on average 20–30 mmHg higher systolic BP than control
mice (without testosterone induction) at the end of the study
(Po0.05). The kidney to body weight ratio in testosterone-
induced transgenic animals was significantly augmented
(Po0.05) compared to wild-type mice. Testosterone treat-
ment also resulted in a significant (Po0.05) increase of
kidney size in wild-type mice but was not associated with
detectable proteinuria. This is not surprising since testoster-
one is a growth factor and routinely increases renal size.
Thus, these results suggest that proteinuria occurs in
transgenic mice only in response to the induction of
transgene expression. In contrast, both male and female
transgenic lines displayed proteinuria (30–36 mg/dl), indicat-
ing ongoing kidney injury (transgenic line #351 not shown,
but similar to line #388). Proteinuria is important since it is a
marker of renal disease.15 Thus, proteinuria following
transgene induction suggests that increased intrarenal
ANG expression is associated with the development of renal
injury.
In the longitudinal study, there was no significant
difference in BP in male and female non-transgenic mice
with or without testosterone induction. The BP of transgenic
mice, however, was significantly elevated after 2 weeks of
induction with testosterone compared to the placebo
controls. The average increase of systolic BP for 83 days
was 20–30 mmHg (Po0.05) compared to their non-trans-
genic littermates or placebo controls. Administration of RAS
blockers significantly reduced the BP in these mice,
indicating that activation of the intrarenal RAS is important
in this process. Perindopril appeared to be more effective
Figure 10 | Hematoxylin–phloxin–saffran staining in male trans-
genic mice after 83 days of induction with testosterone (Original
magnification  400). (a) Uninduced male control littermate,
(b) testosterone-induced male control littermate, (c) uninduced male
transgenic animal, (d) testosterone-induced male transgenic animal,
(e) testosterone-induced male transgenic animalþ losartan, and
(f) testosterone-induced male transgenic animalþperindopril.
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than losartan in lowering BP in female but not in male
transgenic mice.
Since microalbuminuria is an important marker for the
early detection of hypertension- or diabetes-induced nephro-
pathy,15,16 we monitored urinary albumin excretion during
the longitudinal study. Animal experiments have shown that
early detection of microalbuminuria and subsequent treat-
ment with RAS blockers can slow or even prevent disease
progression.16–18 Microalbuminuria appeared only after 75
days of induction in our transgenic animals receiving
testosterone. Prior to day 75, there was no detectable
albuminuria. Microalbuminuria levels reached 0.37 and
0.74 mg albumin/mg of creatinine for females and males at
day 83, respectively. Treatment with RAS inhibitors signifi-
cantly reduced protein levels. Once again, perindopril
appeared to be more effective than losartan in lowering
albumin in females. In males, RAS blockers were also
effective, but perindopril did not confer more advantage
than losartan. To the best of our knowledge, this is the first
report that RAS blockade could prevent HBP and albumi-
nuria (renal injury) in both male and female transgenic mice
with overexpression of rANG gene in RPTs. Taken together,
these observations suggest a link between renal ANG gene
expression, hypertension, and microalbuminuria. It remains
to be seen whether intrarenal RAS activation alone could
induce microalbuminuria independently of systemic hyper-
tension. Studies are under way to test this possibility.
Interestingly, histological examination revealed that the
kidneys of female transgenic mice treated with testosterone
displayed cellular edema, reabsorption of droplets, proximal
tubular hypertrophy, and glomerular proliferation as com-
pared to wild-type non-transgenic controls treated with
testosterone and female transgenic mice treated with placebo.
These findings were not observed in male transgenic mice
irrespective of testosterone treatment. The exact reason(s) for
this sexual dimorphic response is unknown at present,
although gender difference or decreased renin expression in
the kidneys of male transgenic mice, as observed previously,14
may provide some explanation. Perindopril appeared to be
more effective in slowing kidney damage in female mice as
compared to losartan. A similar perindopril effect has been
reported in humans.19,20 To provide additional evidence that
the intrarenal RAS was indeed responsible for the pathology
observed, we measured the levels of plasma renin activity as
well as plasma testosterone. There was no significant change
in plasma renin activity and testosterone levels in the
transgenic animals compared to control littermates (data
not presented).
Although the precise mechanism(s) by which BP increases
and causes kidney injury (albuminuria and RPT hypertro-
phy) in our transgenic mice model remains unclear, several
possible hypotheses arise from these observations. One
hypothesis is that ANG produced in renal proximal tubular
cells (RPTCs) is secreted and converted to Ang II in the
proximal tubular lumen or at a more distal point along the
nephron, since renin could be filtered into the lumen. As
RPTCs also express renin,21 it is conceivable that RPTC-renin
could cleave ANG to produce angiotensin I and then Ang II
by angiotensin-converting enzyme. Subsequently, Ang II
could affect BP via stimulation of the sodium/hydrogen
exchanger in RPTs,4,7 or by the activation of epithelial
sodium channels in collecting duct cells,5,6 thereby promot-
ing sodium reabsorption. Furthermore, Ang II could increase
transforming growth factor-b1 gene expression via AT1R in
RPTCs, leading to renal injury (cellular hypertrophy). We
have observed this effect in vitro where Ang II stimulation of
immortalized rat proximal tubular cells induces cell hyper-
trophy.22,23 Indeed, further work is needed to confirm this
possibility.
In conclusion, our data strongly suggest that activation of
the intrarenal RAS alone evokes a significant increase of BP
and leads to renal injury. The administration of RAS blockers
prevents these abnormalities.
MATERIALS AND METHODS
Losartan (a non-peptide Ang II (AT1)-receptor blocker) and
perindopril (an inhibitor of angiotensin-converting enzyme) were
obtained from Dr Ronald D Smith (Dupont Merck, Wilmington,
DE, USA) and Dr Serge Carrie`re (Servier Ame´rique, Laval, QC,
Canada), respectively. COS-7 cells (Green monkey kidney cells) were
obtained from the American Type Tissue Culture Collection
(Rockville, MD, USA). The pKAP2 plasmid that contains the
kidney androgen-regulated promoter (KAP), which is responsive to
testosterone stimulation, is constructed by us (CD Sigmund’s
laboratory) and has been described elsewhere.10,14 Placebo pellets or
pellets containing 5 mg testosterone with a 91-day release schedule
(A-192) were purchased from Innovative Research of America
(Sarasota, FL, USA). Mouse anti-HA (a sequence encoding amino-
acid residues 98–106 (YPYDVPDYA) of human influenza virus
hemagglutinin) monoclonal antibodies (12CA5) were obtained
from La Roche Biochemicals (Dorval, QC, Canada). Rabbit anti-
rANG antibodies were generated in our laboratory (JSD Chan).24
These antibodies are specific for intact rat and mouse ANG (i.e.
55–62 kDa ANG) and do not crossreact with pituitary hormone
preparations or other rat or mouse plasma proteins.24 The plasmid
vector pcDNA 3.1 and oligonucleotides were procured from
InVitrogen, Inc. (Burlington, ON, Canada). Restriction and
modifying enzymes were purchased from either InVitrogen, Inc.,
La Roche Biochemicals, or Amersham-Pharmacia Biotech, Inc. (Baie
d’Urfe´, QC, Canada).
Generation of recombinant rANG-HA fusion protein
A cDNA encoding full-length rANG fused with HA-tag at the
carboxyl terminal and NotI restriction enzyme site attached at both
50- and 30-termini was inserted into the pcDNA 3.1 plasmid at the
NotI site. The orientation of the insert was confirmed by DNA
sequencing (performed at the DNA Sequencing Facility of the
CHUM). The T7 promoter primer (InVitrogen, Inc.) was used in
DNA sequencing. The plasmid pcDNA 3.1/rANG-HA was then
transiently transfected into COS-7 cells with Lipofectamine accord-
ing to the instruction manual provided by the supplier (InVitrogen,
Inc.). The cells were harvested 24 h after transfection and extracted
with lysis buffer containing 1% Triton-100 (Laboratoires MAT,
Montreal, QC, Canada), 0.1% sodium deocyl sulfate (SDS), 150 mM
NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 50 mM
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Tris-HCl, pH 7.5, 1 mM phenylmethylsulphonyl fluoride, and
cocktail inhibitor (1 tablet/10 ml lysis buffer, La Roche Biochemicals,
Dorval, QC, Canada). The extracts were centrifuged at 13 000 g and
41C. The supernatant was taken for quantification of protein
concentration and Western blot analysis.
Western blot analysis
Cellular proteins (30–50 mg) or 1 ml of mouse plasma were loaded on
SDS-10% polyacrylamide gel. After transfer by wet blotting onto a
polyvinylidine difluoride membrane (Hybond-P, Amersham-Pharm-
acia Biotech, Inc.), the membrane was blocked in 5% non-fat milk
powder and 0.05% Tween 20 in phosphate-buffered saline. It was
first blotted with mouse anti-HA monoclonal antibodies and
developed with chemiluminescent developing reagent (Roche
Biochemicals, Inc.). The membrane was then re-blotted with rabbit
anti-rANG polyclonal antibodies and developed with anti-rabbit
horseraddish peroxidase conjugates (HRP) and the avidin–HRP
conjugates according to the protocol of the supplier (Bio-Rad
Laboratories, Richmond, CA, USA).
Generation of KAP2-rANG transgenic mice
A full-length rANG cDNA fused with HA-tag at the carboxyl
terminal and NotI restriction enzyme site attached at both 50- and
30-termini (as described above) was inserted into pKAP2 plasmid at
the NotI site. The orientation of the insert was confirmed by DNA
sequencing. The primer 50 CCA GCC AAC TGT GGA AAA A 30 was
used in DNA sequencing. The final 17 kb KAP2-rANG transgene was
excised by digestion with NdeI and SpeI, purified by agarose gel
electrophoresis, and recovered by gel extraction. The isolated KAP2-
rANG transgene was then microinjected into one-cell fertilized
mouse embryos obtained from superovulated C57Bl6C3H mice,
using a standard procedure (performed at the Clinical Research
Institute of Montreal, Montreal, QC, Canada). Founder mice were
identified by Southern blot analysis of mouse tail genomic DNA
digested with BamHI. The positive transgenic founders were then
crossed with wild-type C57Bl6 mice (Charles River, St-Constant,
QC, Canada) to obtain an F1 generation. Breeding was continued
until homozygous F4 mice were generated.
The mice used in these experiments were 15–20 weeks of age at
the time of data collection. Non-transgenic and sex-matched
littermates served as controls. All animals received standard mouse
chow and water ad libitum. Their care in these experiments met the
standards set forth by the Canadian Council on Animal Care, and
the procedures utilized were approved by the Institutional Animal
Care Committee of the CHUM.
Analysis of transgene expression
Various tissues were harvested and snap-frozen on dry ice. Total
RNA was isolated by TRIzol (InVitrogen) after tissue homogeniza-
tion. Before proceeding with RT, RNA was subjected to DNase-1
treatment (InVitrogen) to remove contaminating genomic DNA.
RNA was subjected to RT-PCR analysis as described previously.25–27
The rANG sense primer (50-CCT CGC TCT CTG GAC TTA TC-30)
corresponding to the nucleotide sequences Nþ 676 to Nþ 695 of
rANG cDNA,28 HA anti-sense primer (50-GGC GTA GTC AGG CAC
GTC GT-30), b-actin forward primer and reverse primer corre-
sponding to the nucleotide sequences Nþ 155 to Nþ 179 of exon 3
(50-ATG CCA TCC TGC GTC TGG ACC TGG C-30) and Nþ 115 to
Nþ 139 of exon 5 (50-AGC ATT TGC GGT GCA CGA TGG AGG
G-30) of the rat b-actin gene,29 respectively, were used for PCR.
Immunohistochemical staining for rANG
Kidneys from neonatal mice were removed immediately after they
were killed. Formalin-fixed, paraffin-embedded kidney sections of
5 mm were deparaffinized in xylene and rehydrated. Immunohisto-
chemical examination was performed by the standard avidin–bio-
tin–peroxidase complex method (ABC Staining System) (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA). Endogenous peroxidase was
inhibited in 1% hydrogen peroxide–methanol for 10 min at room
temperature and followed by trypsin treatment for 8 min in a moist
chamber at 371C. After serum blocking, the sections were incubated
with primary anti-rANG polyclonal antibody (rabbit #16) diluted
1:1000 for 1 h at room temperature; then, biotinylated secondary
antibody was added, followed by the addition of preformed ABC
reagent supplied by kit. The rANG protein was visualized by color
development with 3, 30-diaminobenzidine tetrahydrochloride. All
sections were counterstained with hematoxylin, dehydrated, and
covered with glass slips.
Mouse renal proximal tubule isolation
Animals were killed under CO2. Their kidneys were removed, rinsed
in ice-cold DMEM, decapsulated, and the cortices were separated
from the medulla. Proximal tubules were isolated by Percoll
gradient30 with slight modifications as described previously.31
Physiological studies
Homozygous transgenic mice (males and females) and non-
transgenic littermates were anesthetized with isofurane and
implanted surgically with placebo pellets or pellets containing
5 mg testosterone that was gradually released over 91 days. Before
implantation, bupivacaine HCl (0.25%, Abbott Laboratories,
Montreal, QC, Canada) was applied topically at the incision site.
The pellet was implanted subcutaneously in the back and tunneled
to the nape of the neck with a 10-gauge trocar. The incision was
closed with a stainless steel staple, and the mice were given 2 days to
recover.
After a baseline period and then starting 7 days after the
implantation of testosterone pellets to induce renal rANG expres-
sion, BP was monitored with a BP-2000 tail-cuff pressure machine
(Visitech Systems, Apex, NC, USA) once to twice a week for a period
of 21–83 days, depending on the experimental protocol. However,
before measuring BP, the mice were trained for at least 30 min per
day for 5 days prior to the first BP measurements. Thus, after
assessing baseline BP for 1 week, non-transgenic littermates and
transgenic mice were divided into four equal groups: (1) placebo
(with placebo pellet) (n¼ 4), (2) testosterone (n¼ 4), (3) testoster-
one with losartan treatment (30 mg/kg/day in drinking water, n¼ 4),
and (4) testosterone with perindopril (5 mg/kg/day in drinking
water, n¼ 4). At the end of treatment, body weights were recorded,
and the mice were anesthetized with isofurane, then killed by
cervical dislocation. Trunk blood was collected in chilled tubes
containing EDTA for plasma renin measurement or in tubes
containing clotting agents for serum separation to quantify
testosterone levels (Biochemistry Laboratories, CHUM-Hoˆtel-Dieu,
Montreal, QC, Canada).
Mice were housed in metabolic cages to obtain 24-h urine
samples for assessing proteinuria. Animals had free access to water
and food during this period. The next day, urine volume was
recorded. Proteinuria was estimated by using Chemstrip 9 (La Roche
Biochemicals) and/or albuminuria was assessed with an enzyme-
linkedimmunosorbent assay kit according to the manufacturer’s
protocol (Cedarlane Laboratoires Ltd, Hornby, ON, Canada).
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Several tissues, such as the liver, brain, heart, lungs, spleen, testis,
and ovaries, were collected for RNA extraction and analyzed by RT-
PCR for rANG mRNA expression. The kidneys were weighed
carefully. One kidney was used for immunohistochemistry and the
other for RNA extraction. Kidneys were always taken from the same
side of the animals for different procedures.
Histological studies
Tissues were collected in Tissue-Tek cassettes (VWR Canlab,
Montreal, QC, Canada), dipped immediately in ice-cold phosphate-
buffered saline–4% paraformaldehyde, and fixed for 24 h at 41C.
The cassettes were processed by the Pathology Department at the
CHUM. Briefly, the tissues were dehydrated by successive ethanol
baths (from 50 to 100%), then rehydrated with a mix of toluene and
water (from 50 to 100%). The cassettes are dipped in hot paraffin
solution and embedded for 16 h. The tissue blocks were cut with a
microtome to obtain the desired tissue specimens.
Statistical analysis
Statistical significance between experimental groups was analyzed
initially by Student’s t-test or by one-way analysis of variance and
the Bonferroni test as appropriate. Data are expressed as means7s.e.
Values of Po0.05 were considered to be statistically significant.
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